JPMorgan Upgrades Biogen to Overweight, Raises Target to $300
JPMorgan upgraded Biogen to Overweight from Neutral and raised its price target to $300 from $210. Biogen shares rose 3.5% in premarket trading.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
JPMorgan Upgrades Biogen to Overweight, Raises Price Target to $300
JPMorgan upgraded Biogen to Overweight from Neutral and raised its price target to $300 from $210, citing a more compelling pipeline catalyst outlook and improved long-term growth prospects.